Article
Medicine, General & Internal
Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wrobel, Fritz Offner, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Mark Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings, Marek Trney
Summary: Glofitamab therapy is effective for DLBCL, but more than half of the patients experience grade 3 or 4 adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Vera Rentsch, Katja Seipel, Yara Banz, Gertrud Wiedemann, Naomi Porret, Ulrike Bacher, Thomas Pabst
Summary: CAR T-cell therapy is a significant advancement in treating relapsed B-cell non-Hodgkin lymphomas, but some patients still experience disease progression. There is limited information regarding treatment options and outcomes for patients who relapse after CAR T-cell therapy. This study evaluated the safety and efficacy of using the bispecific CD20xCD3 antibody glofitamab as monotherapy in patients who progressed after CAR T treatment. The results showed that glofitamab treatment was well tolerated and effective, with enhanced residual CAR T-cell activity.
Article
Oncology
Elif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, Muhit Ozcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Fergun Yilmaz, Derya Koyun, Nihan Alkis, Inci Alacacioglu, Mehmet Sonmez, Irfan Yavasoglu, Anil Tombak, Ozgur Mehtap, Fatih Kurnaz, Orhan Kemal Yuce, Volkan Karakus, Mehmet Turgut, Derya Deniz Kurekci, Mesut Ayer, Muzaffer Keklik, Deram Buyuktas, Murat Ozbalak, Burhan Ferhanoglu
Summary: This retrospective study evaluates the effectiveness and safety of glofitamab treatment in diffuse large B-cell lymphoma (DLBCL) patients in Turkey. Some patients showed partial or complete response to the treatment, and some had longer survival periods.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Immunology
Nikeshan Jeyakumar, Melody Smith
Summary: Cellular therapies have revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Autologous CAR T cells have shown promising results in achieving complete remission, but a significant portion of patients still relapse or progress. Allogeneic CAR T cells may offer a solution by addressing the limitations of autologous therapy and providing a more sustainable platform for cell therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Health Care Sciences & Services
Yazeed Sawalha
Summary: This article reviews the advancements in treatments for relapsed/refractory DLBCL, including the efficacy and limitations of CAR T cell and non-CAR T-cell therapies, as well as emerging therapies that have shown promising early results in recent years.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Hematology
Ann-Marie E. Broeske, Koorosh Korfi, Anton Belousov, Sabine Wilson, Chia-Huey Ooi, Christopher R. Bolen, Marta Canamero, Enrique Gomez Alcaide, Ian James, Emily C. Piccione, David J. Carlile, Natalie Dimier, Pablo Umana, Marina Bacac, Martin Weisser, Michael Dickinson
Summary: This study evaluated the clinical activity of a novel antibody called glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma patients and provided evidence of its pharmacodynamic profile, mode of action, and factors associated with clinical response by evaluating biomarkers. The results showed that glofitamab can activate T cells, inhibit tumor cells, and is associated with certain tumor characteristics.
Article
Cell Biology
Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis, Thomas Pabst
Summary: This study reports two cases of mantle cell lymphoma patients who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab. Both patients showed increased circulating CAR T cells and objective responses after glofitamab administration. Therapy with bispecific antibodies might offer an effective and well-tolerated option for patients with mantle cell lymphoma relapsing after CAR T therapy.
Article
Oncology
Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan C. Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
Summary: In this retrospective study, the combination of tafasitamab and lenalidomide showed a significant improvement in overall survival compared to other treatment regimens for relapsed/refractory diffuse large B-cell lymphoma.
CLINICAL CANCER RESEARCH
(2022)
Review
Biotechnology & Applied Microbiology
Haifaa Abdulhaq, Andrew Hwang, Omar Mahmood
Summary: The prognosis for R/R DLBCL has historically been poor, but the development of CD19 directed therapies has significantly improved outcomes. CAR-T therapy has revolutionized treatment, but faces barriers and limited accessibility. Tafasitamab-lenalidomide has shown significant efficacy and durable responses in ineligible R/R DLBCL patients, providing an alternative to CAR-T for those with comorbidities or rapid disease progression. This review focuses on approved and recent targeted treatment options for R/R DLBCL, emphasizing CAR-T alternatives like Tafasitamab-lenalidomide.
ONCOTARGETS AND THERAPY
(2023)
Review
Immunology
Linyan Tian, Cheng Li, Juan Sun, Yixin Zhai, Jinhuan Wang, Su Liu, Yanan Jiang, Wenqi Wu, Donghui Xing, Yangyang Lv, Jing Guo, Hong Xu, Huimeng Sun, Yuhang Li, Lanfang Li, Zhigang Zhao
Summary: This study compared the efficacy of CAR-T cell therapy with auto-HSCT in R/R DLBCL patients. The results showed that patients undergoing CAR-T cell therapy had a better overall response rate and partial response compared to those treated with auto-HSCT. However, in terms of long-term treatment superiority, auto-HSCT showed better advantages in terms of 1-year and 2-year overall survival and progression-free survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Florian Lueke, Dennis C. Harrer, Karin Menhart, Daniel Wolff, Ernst Holler, Dirk Hellwig, Wolfgang Herr, Matthias Grube, Martin Vogelhuber, Albrecht Reichle, Daniel Heudobler
Summary: MEPED therapy is well tolerated with low toxicity and highly effective in relapsed/refractory cHL, including severely comorbid patients. Among the three newly treated patients, CT scans showed partial remissions after 2-5 months on MEPED treatment. One patient achieving partial remission became eligible for alloHSCT, while the other two continued treatment with MEPED, eventually achieving continuous complete remission (cCR).
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Hematology
Pallawi Torka, Adrienne Groman, Jerry Wong, Jenna Nichols, Angela Kader, Cory Mavis, Andrea Anampa-Guzman, Sheila Jani Sait, AnneMarie Block, Eugene Przespolewski, Alice Mohr, Ian Lund, Kenneth McWhite, Jessica Kostrewa, Joseph DeMarco, Michael Johnson, Andrea Darrall, Roshneke Thomas, Suchitra Sundaram, Paola Ghione, Alan Hutson, Francisco J. Hernandez-Ilizaliturri
Summary: The study showed that novel salvage regimens are needed in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients previously treated with rituximab plus R-CHOP. Carfilzomib (CFZ) can overcome rituximab chemotherapy resistance and has shown efficacy in preclinical models. This study evaluated the safety and efficacy of CFZ in combination with C-R-ICE in high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) eligible patients with R/R DLBCL. The results showed that CFZ in combination with C-R-ICE had a high overall response rate and significantly better outcomes in patients with non-GCB DLBCL.
Article
Oncology
Yasuhito Terui, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Hirohiko Shibayama
Summary: The study demonstrated the efficacy and safety of the combination of Polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma who were ineligible for autologous stem cell transplantation.
Article
Oncology
Eliza A. Hawkes, Tycel Phillips, Lihua Elizabeth Budde, Armando Santoro, Nakhle S. Saba, Fernando Roncolato, Gareth P. Gregory, Gregor Verhoef, Fritz Offner, Cristina Quero, John Radford, Krzysztof Giannopoulos, Don Stevens, Aron Thall, Bo Huang, A. Douglas Laird, Robin Sandner, Stephen M. Ansell
Summary: The study aimed to evaluate the efficacy of avelumab in combination with other drugs for the treatment of R/R DLBCL, but the results showed poor clinical activity, leading to an early termination of the study.
Article
Oncology
Colton Ladbury, Savita Dandapani, Claire Hao, Mildred Fabros, Arya Amini, Sagus Sampath, Scott Glaser, Karen Sokolov, Jekwon Yeh, John H. Baird, Swetha Kambhampati, Alex Herrera, Matthew Mei, Liana Nikolaenko, Geoffrey Shouse, Lihua E. Budde
Summary: Bridging therapy (BT) with systemic therapy (ST), radiation therapy (RT), or combined-modality therapy (CMT) is commonly used before chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). This study evaluated the impact of BT in a large cohort of LBCL patients who received commercial CAR T-cell therapy, showing that BT did not compromise outcomes and patients with limited disease treated with RT had favorable outcomes. Prospective studies are needed to optimize the treatment strategy for relapsed/refractory LBCL patients planning to undergo CAR T-cell therapy.
